Financials Arch Biopartners Inc. Toronto S.E.
Equities
ARCH
CA03938C1041
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.69 CAD | -0.59% |
|
+2.42% | +14.19% |
06-27 | Arch Biopartners Up More Than 2% After Announcing GMP Manufacturing Of Cilastatin Drug Product | MT |
06-27 | Arch Biopartners Inc. Announces GMP Manufacturing of Cilastatin Drug Product | CI |
Valuation
Fiscal Period: September | 2021 | 2024 | 2025 |
---|---|---|---|
Capitalization 1 | 106.9 | 106.7 | - |
Enterprise Value (EV) 1 | 106.9 | 106.7 | 106.7 |
P/E ratio | -90.8 x | -23.9 x | -23.9 x |
Yield | - | - | - |
Capitalization / Revenue | - | 53.3 x | 53.3 x |
EV / Revenue | - | 53.3 x | 53.3 x |
EV / EBITDA | - | -21.3 x | -8.89 x |
EV / FCF | - | - | - |
FCF Yield | - | - | - |
Price to Book | - | - | - |
Nbr of stocks (in thousands) | 61,962 | 63,851 | - |
Reference price 2 | 1.725 | 1.671 | 1.671 |
Announcement Date | 28/01/22 | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: September | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|
Net sales 1 | - | - | - | 2 | 2 |
EBITDA 1 | - | - | - | -5 | -12 |
EBIT | - | -1.389 | - | - | - |
Operating Margin | - | - | - | - | - |
Earnings before Tax (EBT) | - | - | - | - | - |
Net income | -1.17 | - | -3.327 | - | - |
Net margin | - | - | - | - | - |
EPS 2 | -0.0190 | - | - | -0.0700 | -0.0700 |
Free Cash Flow | - | - | - | - | - |
FCF margin | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 28/01/22 | 30/01/23 | 29/01/24 | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: September | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 |
---|---|---|---|---|---|---|---|---|---|---|
Net sales | 0.4347 | 2.531 | 0.1164 | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - |
EBIT | -2.211 | -0.896 | -0.4743 | - | - | - | - | - | - | - |
Operating Margin | -508.54% | -35.4% | -407.59% | - | - | - | - | - | - | - |
Earnings before Tax (EBT) | -2.158 | -0.9624 | -0.4508 | - | - | - | - | - | - | - |
Net income | -2.158 | -0.9624 | -0.4508 | -0.7832 | - | - | - | - | - | - |
Net margin | -496.37% | -38.02% | -387.37% | - | - | - | - | - | - | - |
EPS 1 | -0.0350 | -0.0150 | -0.007000 | - | -0.0180 | -0.0200 | -0.0200 | -0.0200 | -0.0200 | -0.0200 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 01/03/23 | 30/05/23 | 29/08/23 | 29/02/24 | 31/05/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: September | 2021 | 2023 | 2024 | 2025 |
---|---|---|---|---|
Net Debt | - | - | - | - |
Net Cash position | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - |
Free Cash Flow | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - |
Assets | - | - | - | - |
Book Value Per Share | - | - | - | - |
Cash Flow per Share | - | - | - | - |
Capex | - | - | - | - |
Capex / Sales | - | - | - | - |
Announcement Date | 28/01/22 | 29/01/24 | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.65% | 39.1B | |
-8.69% | 38.76B | |
+27.47% | 31.24B | |
+11.42% | 25.9B | |
-13.50% | 25.8B | |
+44.44% | 14.06B | |
+35.50% | 13.12B | |
-7.37% | 11.32B | |
-12.92% | 10.68B |
- Stock Market
- Equities
- ACHFF Stock
- ARCH Stock
- Financials Arch Biopartners Inc.